Document Type

Article

Publication Date

10-9-2023

Comments

This article is the author’s final published version in JEADV Clinical Practice, Volume 3, Issue 1, Mar 2024, Pages 249-252.

The published version is available at https://doi.org/10.1002%2Fjvc2.282. Copyright © 2023 The Authors. JEADV Clinical Practice published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.

Publication made possible in part by support through a transformative agreement between Thomas Jefferson University and the publisher.

Publication made possible in part by support from the Jefferson Open Access Fund

Abstract

Background

Monkeypox (Mpox) infections are considered a public health emergency, prompting the need for the administration of a preventative vaccine to high-risk individuals.

Objectives

To describe the clinical course of dermatologic reactions to Mpox vaccine over time.

Methods

Seven recipients of the Mpox vaccine, administered via intradermal injection, were observed over time, and the dermatologic reactions to this vaccine were recorded.

Results

All seven recipients experienced mild to moderate localized reactions to Mpox vaccine to either the primary or booster injections. These reactions were characterized by erythema, induration and pruritus. These reactions eventually healed without any sustained reactions, eschar or scarring. None of the recipients experienced systemic reactions or widespread cutaneous eruptions.

Conclusions

Intradermal injections of Mpox vaccine result in mild to moderate injection site reactions, most likely representing a vigorous cell-mediated immune response. In all cases, the injection sites healed without complications.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

Language

English

Download

Share

COinS